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Abstract: Vitamin D (VitD), which is well known for its classic role in the maintenance of 
bone mineral density, has now become increasingly studied for its extra-skeletal roles. It has 
an important influence on the body’s immune system and modulates both innate and adaptive 
immunity and regulates the inflammatory cascade. In this review our aim was to describe 
how VitD might influence immune responsiveness and its potential modulating role in 
vaccine immunogenicity. In the first instance, we consider the literature that may provide 
molecular and genetic support to the idea that VitD status may be related to innate and/or 
adaptive immune response with a particular focus on vaccine immunogenicity and then 
discuss observational studies and controlled trials of VitD supplementation conducted in 
humans. Finally, we conclude with some knowledge gaps surrounding VitD and vaccine 
response, and that it is still premature to recommend “booster” of VitD at vaccination time 
to enhance vaccine response. 
Keywords: vitamin D; vaccine; immunogenicity; immune cells; adaptive immunity; innate 
immunity; cholecalciferol; calcitriol; 25(OH)VitD 
 
1. Introduction 
Vitamin D (VitD) is fat-soluble vitamin, unique in that it is primarily derived from the action of  
UV-B on the epidermis (VitD3 only) rather than absorbed from the diet (VitD2 and D3). Only plants and 
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fungi synthetize VitD2 while VitD3 is physiologically produced in relatively large quantities in humans 
and the majority of vertebrates [1]. Because, worldwide, naturally occurring dietary sources of VitD are 
very limited, and food fortification is often suboptional, inconsistent, inadequate, or non-existent, 
individuals mainly depend on sunlight exposure for most of their requirements [2]. Of course, both type 
of VitD (D2 and D3) supplements are available for over-the-counter purchase; VitD3 is the type that most 
experts believe should be utilized in practice. Indeed, VitD3 is more effective at raising and maintaining 
the 25(OH)VitD serum level. Compared to D3, VitD2 does not bind as well to the VitD receptor (VDR) 
in human tissues. VitD3 is also more stable on the shelf compared to D2 as it is more likely to remain 
active for a longer period of time and when it is exposed to different conditions (i.e., temperature, 
humidity, and storage). This has contributed to VitD3 being the most utilized form of VitD in clinical 
trials [3]. 
Through the action of UV-B, VitD is metabolized from 7-dehydroxycholesterol in the epidermis and 
converted at first in the liver to form its main circulating form. 25(OH)VitD which is then transported 
into the blood stream to the proximal tubule of the kidney where it is 1-α hydrolysed to form 
1,25(OH)2VitD by the cytochrome P450 27B1 (i.e., CYP27B1 or 25-hydroxyvitamin D 1-α  
hydroxylase) [4]. Once activated, VitD interacts with its specific receptor (i.e., the VDR) in order to 
regulate expression and transcription of many genes and down stream products. This specific receptor, 
which is also known as NR1I1 (nuclear receptor subfamily 1, group I, member 1), is localized in the 
nucleus of various cell types [5,6]. Upon activation, the VDR forms a heterodimer with the retinoid-X 
receptor and binds to hormone response elements on DNA resulting in expression or transrepression of 
specific gene products. 
The beneficial effects of VitD on skeletal homeostasis are very well documented, however the optimal 
serum 25(OH)VitD level at which these effects are obtained is still hotly debated among researchers in 
the world of VitD [7–9]. It is generally recommended to maintain the serum level above 75 nmol/L (i.e., 
30 ng/mL) [8], which is the VitD serum concentration associated with maximal parathyroid hormone 
(PTH) suppression [9,10]. Consequently, a serum concentration <50 nmol/L (i.e., <20 ng/L) is 
considered as deficient and between 50 to 75 nmol/L (i.e., 20 to 32 ng/L) as insufficient [11]. These 
current target serum concentrations were however determined for its application in bone health, but it is 
now becoming more and more clear that the tissue levels of VitD are dissociated from the serum levels 
that control VitD effects. The recent dramatic increase of data highlighting the extra-skeletal benefits of 
VitD and poor health outcomes associated with impaired VitD status has further stimulated the debate 
around the serum threshold for maximum health [7]. Indeed, the exact serum level that is associated with 
full tissue saturation is not known yet and consequently, the effective dose eliciting an effect on the 
immune system in vivo, for example, remains to be determined [10,12]. This question is also relevant 
for the role of VitD in inducting differentiation and inhibiting proliferation of various normal and cancer 
cells by regulating gene expression in multiple signaling pathways in a large number of tissues [12–14]. 
Recently, the potential role of VitD in modulating host defense to foreign antigens and pathogens has 
been particularly reported. This arises from the discovery that: (i) the immune system cells are able to 
produce CYP27B1 and to convert 25(OH)VitD into 1,25(OH)2VitD; (ii) the majority of cells composing 
both arms of the immune system (i.e., innate and adaptive immunity) express VDR, mainly after they 
themselves have been stimulated; (iii) impaired VitD status which is common in many populations 
across the globe contributes to the burden associated with different pathogen infections; and (iv) the 
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current body of evidence supports the view that VitD supplementation holds promise as a risk-modifying 
intervention in some infectious diseases [7,14–16]. 
The aim of this review is to describe how VitD regulates the immune response and its potential 
immumodulating roles with a specific focus on vaccine immunogenicity. Thus, we first consider the 
literature providing molecular and genetic supports to the idea that VitD status modulates innate and 
adaptive immune responses and hence vaccine immunogenicity. Then we discuss observational and 
control studies of VitD supplementation on vaccine response and effectiveness in human. Finally we 
conclude with some of the knowledge gaps surrounding VitD and vaccine response that should be  
further addressedl. 
2. The Immune System: The Art of War 
The immune system is crucial for human health and survival. With a suboptimally functioning 
immune system, even minor pathogens may prove fatal. Successful immunity requires a network of cells 
and effector molecules working together against invading foreign antigens in the daily battle with 
microorganisms and pathogens. Those cellular components are bone marrow derived B-cells and thymus 
derived T-lymphocytes that form part of the adaptive immune system; and macrophages, dendritic cells 
(DCs), granulocytes, and natural killer (NK) cells which compose the innate arm. In response to 
unknown or foreign antigens whatever their origins (e.g., pathogens, cancers and/or vaccines), a number 
of cytokines are produced by the cellular component among which are interleukin (IL) 1, IL-6, tumor 
necrosis factor α (TNFα), and interferon γ (INFγ). Normally, innate immunity cells first sense antigens 
through their toll like receptors (TLR), which once activated, induce the production of soluble mediators 
that are known to have systemic effects. Phagocytes (i.e., macrophages, neutrophils, NK cells), with 
their ability to engulf foreign particles, are central to the innate immune response, which is a nonspecific 
immune response. Once activated, the innate immune response calls upon T- and B-lymphocytes that 
increase the power and focus of the immune response. This contribution to defense is called the adaptive 
immune response because it is organized around ongoing attack and adapted to the nuances of foreign 
antigens. Consequently, adaptive immunity provides a highly specialized and specific system of defense 
against one particular antigen. Conversely this is of little effect against an attack associated with different 
antigen. This explains, for example, why optimal protection from influenza vaccine is so dependent on 
the exact matching between circulating influenza strains and the antigens contained in the vaccine. The 
most important consequence of an adaptive immune response is the establishment of a state of 
immunological memory (called primary response). Immunological memory is the ability of the immune 
system to respond more rapidly and effectively to pathogens that have been encountered previously. It 
reflects the preexistence of a clonally expanded population of antigen-specific lymphocytes, which 
persist in the body. Memory responses, which are called secondary, tertiary, and so on, depending on 
the number of exposures to antigen, also differ qualitatively from primary responses. This is particularly 
clear in the case of the antibody response, where the characteristics of antibodies produced in secondary 
and subsequent responses are distinct from those produced in the primary response to the same antigen. 
Memory T-cell responses have been harder to study, but can also be distinguished from the responses of 
naive or effector T-cells [17]. This long-lasting memory response is the aim of vaccination and 
immunization programs at individual and population levels respectively [18]. 
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3. Immunomodulating Role of VitD in Host Protection 
The finding that the majority of immune cells can express VDR and part of them produce CYP27B1, 
has raised the idea that VitD could have pleiotropic effects on human immunity [12,14,19]. As depicted in 
Figure 1, it is now clear that VitD has effects on both arms of the immune system and moreover those 
effects are not limited to the classic endocrinal pathway of 1,25(OH)2VitD. Indeed, in addition it is also 
important to consider intracrine (i.e., VitD acts inside a cell) and paracrine signaling pathways (i.e.,  
cell-cell communication in which a cell produces a signal to induce changes in nearby cells, modulating 
the behaviour or differentiation of those cells) that are subject to distinct set of modulatory signals [7,20]. 
Through those pathways, VitD is able to modulate innate and adaptive immunity as an immune switch 
hard to turn on, but easy to turn off. Indeed, VitD improves appropriate immune system communication 
by making it harder for foreign antigen to trigger an inflammatory response and also makes it easier to 
turn off the inflammatory cascade once it is initiated. It is, however, very important to note that most of 
the data presented below results from laboratory based in vitro studies in which exogenous 
1,25(OH)2VitD was added at levels usually above physiological levels [7]. This therefore raises the 
question of whether VitD effectively interferes at physiological concentrations with immune cells and 
also suggests that intracellular synthesis of 1,25(OH)2VitD and subsequent intracrine activity could be 
more effective in achieving these tasks [7]. 
 
Figure 1. Cont. 
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Figure 1. Mechanisms by which 25(OH)VitD and 1,25(OH)2VitD modulate innate and 
adaptive immune response (up) and overview of immunomodulatory actions on monocytes 
and macrophage; dendritic cells; and effector and memory T and B-cells (down). All these 
cells possess the enzyme (CYP27bB1) for hydroxylation steps to generate 1,25(OH)2VitD. 
Through endocrine, intracrine and paracrine mechanisms, the active form of VitD binds to 
the VitD receptor (VDR) to induce a wide range of immunological effects (adapted from 
Lang et al. [7]). 
3.1. VitD and Innate Immunity 
As depicted by the upper part of Figure 1, target cells such as monocytes/macrophages and DCs 
directly utilize circulating 25(OH)VitD for intracrine activity. In addition to phagocytosis of the foreign 
antigen, these cells also sense antigens through their TLRs which once activated up regulate the 
expression of genes that code for the VDR and CYP27B1 [21]. In DCs, the intracrine activity of VitD 
inhibits maturation and thereby modulates CD4+ T-cell function. The helper T-cell (Th) response is also 
modulated in a paracrine fashion, with 1,25(OH)2VitD acting on VDR-expressing CD4+ T-cells. 
Neutrophils, which do not express CYP27B1, are likely to be affected by circulating levels of the active 
form of VitD synthesized by the kidneys. VDR-expressing CD4+ T-cells are also potential targets for 
systemic 1,25(OH)2VitD [20]. The lower part of the Figure 1 specifically shows an overview of how 
25(OH)VitD and 1,25(OH)2VitD modulate monocytes and macrophages, and DCs activation in terms 
of VDR, CYP27B1, CYP24A1 (i.e., the enzyme degrading 1,25(OH)2VitD), production of soluble 
mediators, proliferation and maturation, and the expression of cell membrane receptors and through 
endocrine, paracrine, and intracrine mechanisms [14,22]. The active form of VitD also inhibits TLRs 
expression so inducing a state of hyporesponsiveness to antigen-induced molecular cascades. This could 
be considered as a negative feedback mechanism self-limiting excessive TLR activation and 
inflammation [23]. In addition, 1,25(OH)2VitD enhances antibacterial effect by interacting with the 
promoter of cathelicidin (hCAP) [15]. It so promotes microbial killing in phagocytic vacuoles and 
chemioattraction for neutrophils and monocytes [24]. However, in order to activate hCAP and enhance 
macrophage function, it is necessary to reach sufficient levels of circulating 25(OH)VitD [25]. Similarly, 
epithelial cells, trophoblasts and decidual cells are able to respond to an intracrine hydroxylation  
of 25(OH)VitD to promote antibacterial responses but they can also respond to systemic  
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1,25(OH)2VitD [26]. Systemic 12,25(OH)2VitD may also induce immune tolerance by down-regulating 
pro-inflammatory cytokines in myeloid DCs, such as the cluster of differentiation (CD)-40, CD-80,  
CD-86, major histocompatibility complex (MHC) class II, CD-54, IL-12, IL-23p40 and the C-C motif 
chemokine ligand (CCL) 17 [27]. 
3.2. VitD and Adaptive Immunity 
The tissue-specific synthesis of calcitriol from circulating 25(OH)VitD has been shown to be 
important for both T-cells and B-cells immune response. As presented in Figure 1, once activated, DCs 
induces intracellular activation of 25(OH)VitD, which by intracrine activity inhibits DCs maturation. 
Thereby 1,25(OH)2VitD through intracrine and paracrine actions permits induction and modulation of 
an initial Th-response [27]. In this scenario, by acting as an inhibitor of maturation, 1,25(OH)2VitD 
inhibits T-cells proliferation [28]. Thus, the calcitriol signaling represses the transcription of genes 
encoding Th1 response-like cytokine (i.e., INFγ which activates cell-mediated immunity—Macrophage, 
Cytotoxic T-cell, NK cells—and production of opsonizing antibodies by B-cells—to induce protection 
against intracellular pathogen) [29,30] and Th17 (i.e., IL17 to provide anti-microbial immunity at 
epithelial and mucosal barriers) [31] in order to polarize the CD4+ T-cells responses toward a more 
regulatory Th2 (i.e., IL2 which activate humoral-mediated immunity by the production of neutralizing 
antibodies by B-cells to induce protection against extracellular pathogen) [32] or Threg phenotypes [14,33]. 
These two last phenotypes are considered key components of VitD capacity to suppress Th1-driven 
autoimmunity responses [28,33]. Th17 cells also play a crucial role in combating certain pathogens  
(i.e., Candida albicans, Cryptococcus neoformans, Helicobacter pilory, Klebsiella pneumoniae,  
M. tuberculosis and Staphylococcus [34]) but they have also been linked to tissue damage and 
inflammation [35,36]. Thus it seems that 1,25(OH)2VitD contributes to maintains self-tolerance  
by damping overly zealous adaptive immune system responses while enhancing protective innate 
responses [7]. However, the exact mechanisms by which variations in VitD status may influence T-cell 
functionalities are far to be fully elucidated [7]. 
Initially, it was though that the anti-proliferative effect of 1,25(OH)2VitD on B-cells was an indirectly 
mediated by CD4+ T-cells [14]. Recent in vitro analysis however observed that B-cells were capable of 
intracrine responses. Moreover, VDR expression in B-cells seems to also be regulated by 1,25(OH)2VitD 
suggested that the active form of VitD exerts differential effects on activated versus resting B-cells with 
probably different effects according to individuals’ levels of serum 1,25(OH)2VitD [37]. Indeed, the 
inhibitory effects mediated by the up-regulation of the VDR, as presented in Figure 1 (down), requires a 
certain level of VDR engagement to induce the anti-proliferative effect. Interestingly, CYP27B1 mRNA 
was also found expressed in resting B-cells. Inversely, CYP24A1 was found significantly up regulated 
following the incubation of human B cells with 1,25(OH)2VitD. This suggests that the activity of VitD 
might be influenced not only by VDR expression but also by the capacity to degrade the active molecule. 
In contrast to the VDR, CYP24A1 was not altered by B-cell activation, demonstrating that human B 
cells can respond to 1,25(OH)2VitD directly. The increased susceptibility of activated B cells to many 
of the effects of 1,25(OH)2D3 might reflect the up-regulation of VDR but not CYP24A1 by these  
cells [37]. 25(OH)VitD has similar effects on purified B-cells compared with the active form, but at 
higher concentrations [14]. Finally, 1,25(OH)2VitD limits ongoing B-cell proliferation and modulates 
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B-cell responses. Its effects on plasma cell and memory cell differentiation however result from the 
suppression of ongoing B-cell proliferation [38], which is required before the differentiation steps can 
occur [39]. Other B-cells targets modulated by 1,25(OH)2VitD include IL-10 [40] and the chemokine 
receptor CCR10 [41], suggesting that B-cells responses to VitD are extended to regulating mucosal 
immunity [22,31]. 
3.3. Mechanisms by Which VitD May Induce Anti-Infection Protection 
Recent studies, for the most part conducted in animal models and ex vivo human cells, provide insight 
into the involvement of VitD deficiency and its supplementation in the anti-microbial response to various 
bacterial (e.g., Helicobacter pylori, Pseudomonas aeruginosa, Bordetella bronchoseptica, Salmonella, and 
Shigella) and viral infections (e.g., Influenzae, Respiratory Syncytial Virus, Human Immunodeficiency 
Virus, and Hepatitis C virus) [7]. However, based on the ability of circulating 25(OH)VitD and 
1,25(OH)2VitD to modulate innate and adaptive immune response (i.e., suppression of the oxidative 
burst, Th1-mediated and B-cell immune responses), it would be expected that VitD impairs the host 
defenses to pathogens. Indeed, the Th1/Th17 immune responses are protective during infections [34] 
and 1,25(OH)2VitD would be predicted to increase Threg cells [42]. Moreover, analyses in VDR  
knock-out, wild-type and VitD deficient mice do not support either a beneficial or harmful effect of 
1,25(OH)2VitD on host immunity with respect to a large range of pathogens (e.g., Listeria monocytogenes, 
Leishamania major, Mycobacterium Bovis, Mycobacterium Tuberculosis, Candida Albicans,  
Herpes simplex, Shistosoma mansoni, and Bordetella pertussis) that require either a Th1/Th17 or  
Th2-mediated immune response [7]. Finally, it appears that optimal VitD status has key 
immunomodulatory properties in infectious disease settings, by down-regulating excessive and therefore 
toxic cytokine responses while allowing the clearance of various pathogens through the production of 
antimicrobial peptides [14]. The capacity of the active form of VitD to regulate innate immunity and to 
induce production of hCAP or β-defensin [20] suggests a less straightforward outcome of any changes 
of 25(OH)VitD and/or 1,25(OH)2VitD. In monocytes/macrophages, the activation of TLRs induces 
expression of VDR and localized synthesis (i.e., intracrine) of 1,25(OH)2VitD [20], that in turn, enhances 
hCAP synthesis [43]. Complementary studies have demonstrated that hCAP serves as a mediator of 
VitD-induced autophagy [31]. Finally effective innate immunity against many bacterial pathogens 
requires macrophage responses that up regulate phagocytosis and direct antimicrobial pathways [44].  
It is also interesting to note that hCAP exhibits antiviral properties [45]. So it might enhance protection 
against viral diseases such as influenza [46] but without confirmation by in vitro or in vivo studies  
yet [15]. This VitD-associated induction of hCAP has been also reported in human cell types outside the 
immune system (e.g., keratinocytes, gastrointestinal and bronchial epithelial cells, myeloid cell lines, 
decidual and trophoblastic cells [7]]. Thus, some battles against pathogens at mucosal surfaces seem also 
to be regulated by VitD [31]. 
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4. VitD Status and Vaccine Immunogenicity 
4.1. Good Immune Response: The Key to Success of Vaccinations 
Vaccines are powerful public health tools providing tremendous benefits in protecting vulnerable 
populations from life-threatening infectious diseases worldwide. Indeed, with the exception of safe water, 
no other modality, not even antibiotics, has had such a major positive impact on morbidity and mortality 
reduction [18]. With the introduction of several successful vaccines during the 20th century, major 
achievements included the development of the polio vaccine in the 1950s and the eradication of smallpox 
during the 1960s and 70s have been obtained. While the latter has contributed to the prevention of  
300 million cases and probably saved 100 million lives, the incidence of poliomyelitis has been reduced 
by 100% and by 90% for diphtheria, tetanus, measles, mumps and rubella [47]. As depicted in Figure 2, 
immunization by vaccination stimulates an immune response through the activation of both innate and 
adaptive immunity. The administration of vaccine antigen (with or without adjuvant and whatever the 
route of administration) first induces the activation of innate immune response at the site of injection. 
Vaccine antigens are then captured, processed, and presented by antigen-presenting cells (APCs; i.e., 
macrophages and DCs), which migrate into lymph nodes where they induce activation and clonal 
expansion of naïve CD4+ and CD8+ T-cells (helper and cytotoxic T-cells respectively). The subsequent 
activation and differentiation of naïve B-cells is induced by CD4+ T-cells, which differentiate into 
memory B-cells and antibody-secreting B-cells. Finally long-term immunity is maintained by memory 
B and T-cells (CD4+ and CD8+) in the blood stream and lymph nodes, as well as in the bone marrow 
by long-lived plasma cells and memory T-lymphocytes [47]. 
However, being vaccinated does not guarantee full protection from disease at all times. It is known 
and accepted that in younger infants and older adults vaccines are much less effective [48,49]. Although 
an individual’s age is a major contributor, there is no single cause of vaccine failure in the general 
population. Rather, there is a compilation of events, which include dysregulation of specific facets of 
human immunity and/or hormonal pathway, chronic inflammation, protein-energy malnutrition and/or 
micronutrients and vitamin deficiencies [47,48]. However, this list is far from a comprehensive 
understanding of the mechanisms and kinetics of the process that contributes to long-term memory and 
protection following vaccination. 
The inability of the immune system to provide adequate protection from infection is however a feature 
of normal aging populations and the elderly more particularly. As a consequence, these populations 
demonstrate less effective response to vaccination because of the age-associated remodeling of the 
immune system [50]. Many studies have been carried out to find factors that contribute to the 
immunosenescence process. Results have identified causes related to DCs; T- and B-cell production, 
function as well as repertoires; and NK cells [47]. While the role played by nutritional status (i.e., micro 
and macro-nutrition) and comorbidities has been investigated, whether the lower vaccine effectiveness 
of the elderly is related or not to VitD status, or whether VitD deficiency just further impinges a state of 
immune vulnerability, are still important but unsolved questions [4]. 
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Figure 2. Schematic representation of the vaccine immune response. Administration of 
vaccine antigens induces the activation of the innate immune system. Antigens are first taken 
up by antigen-presenting cells (1). This local innate immune response facilitates maturation 
of dendritic cells (DCs) (2). Mature DCs migrate into lymph nodes (3), where they induce 
activation and clonal expansion of naive CD4+ (4) and CD8+ (5) T-cells. The activation and 
differentiation of naive B-cells is induced by antigen and CD4+ T helper cells (6) as well. 
Naive B-cells differentiate into memory B-cells and antibody-secreting B-cells (7). (Adapted 
from Lang et al. [47]). 
4.2. Translating Immunomodulatory Roles of VitD in Vaccine Response 
With specific regard to vaccination the potential effects of VitD on vaccine response (see Figure 1) 
might be mediated via its action on APCs with the most potent reported effects on DCs [50,51].  
Not only on activation via TLRs by vaccine antigen (with or without adjuvant) DCs up-regulate 
CYP27B1 [21] but by inducing T-cell proliferation and cytokine production. The latter results in 
inhibition of the Th1-like cytokines (IL-2, IFNγ), increase of the Th2-like cytokines (IL4, IL5, IL10 and 
IL13), and in production of Th17-like cytokine (IL17) secretion [52,53], and finally through indirect 
effects on B-cell homeostasis, proliferation and immunoglobulin production [37]. So although 
1,25(OH)2VitD would seem to directly blunt B-cell functions (see Figure 1), it would, paradoxically, 
stimulate vaccine effectiveness through its effects on innate immunity [15]. 
Vaccine antigens
intramuscularly injected
Site of injection
Lymphatic vessel
(3)
(1)
(1)
(2)
macrophage
immature DC mature DC
pro-inflammatory 
cytokines
Lymph node
Blood vessel
Bone marrow
(4)
(5)(6)
(7)
memory CD4+ T-cell memory CD8+ T-cell
long-lived plasma cell
memory and 
effector CD4+ T-cells
memory and 
effector CD8+ T-cells
antibody-secreting B-cellmemory B-cell
naive B-cell
naive CD4+ T-cell
naive CD8+
T-cellfollicular DC
 
Nutrients 2015, 7 2053 
 
Recent studies have confirmed the potent effects of VitD on cytokine production and in regulating 
normal innate and adaptive immune functions in animals and humans [15,54,55]. In animal models, it 
has been observed that locally produced 1,25(OH)2VitD induces migration of DCs from the site of 
vaccination to non-draining lymphoid organs, where they can stimulate antigen-specific T- and B-cells 
to mount a strong and persistent antibody response to diphtheria vaccination [56,57]. Co-administration 
of 1,25(OH)2VitD with trivalent influenza vaccine in mice enhances both mucosal and systemic specific 
antibody response, and subsequently the animals’ ability to neutralize live influenza virus instilled in the 
nose [58,59]. Other studies, also conducted in animal models or with ex vivo human cells have 
highlighted the role played by VitD deficiency and its supplementation on immune response to 
vaccination (e.g., hepatitis B, measles, rubella, and BCG vaccinations) [60–63]. 
5. What Do We Know from Clinical Trial and Observational Studies? 
Consecutively to the potent effects of VitD on cytokine production and regulation of immunity, the 
influence of its serum level and multiple VDR SNPs/haplotype on the vaccine immunogenicity and their 
potential roles as vaccine enhancer have been investigated in humans as summarized in Table 1. When 
1.0 μg of 1,25(OH)2D3 was intramuscularly co-administered with influenza vaccine at the site adjacent 
to vaccination in a randomized control-study conducted in 175 healthy human volunteers  
(18–49 years of age), humoral immunity was not enhanced [64]. Serum influenza hemagglutination 
inhibition (HAI) titres were used to assess the ability of the host immune response to neutralize the 
infectivity of the virus [65]. However three important limitations are drawn from this study. First, the 
subjects were young and healthy and since serum 25(OH)VitD status was not measured at baseline, it is 
most probable that these individuals were neither VitD deficient nor insufficient. This reinforces the idea, 
as previously mentioned with respect to the host defense against pathogens, that higher than optimal 
levels (i.e., 40 ng/mL or 100 nmol/L) do not seem to provide an additional benefit [15,66]. Second, 
significant pre-vaccination HAI titres were measured in nearly all subjects. This indicates that the 
subjects had considerable immunity to three vaccine influenza strains before their vaccination. Since a 
clear inverse relationship exists between pre-immunization serum HAI and antibody response after 
vaccination this could have masked the potential vaccine-enhancing effect of 1,25(OH)2VitD [15]. Third, 
VitD supplementation and vaccine were simultaneously administered; the delay between the two 
injections was too limited to expect any beneficial biological effects on DCs, on macrophages, or on 
cells composing the adaptive immunity. This is true even if the active form of VitD was considered in 
the study, because the endocrine activation pathway, as depicted in Figure 1 does not seem to be the 
main mechanism by which 1,25(OH)2VitD modulates innate immunity. More recently, the influence of 
VitD on influenza vaccine immunogenicity in HIV was assessed using data from a phase 3 randomized 
trial conducted during the 2008–2009 influenza season [67]. One third of participants were on 
supplemental VitD at baseline. Neither seroconversion nor seroprotection rates were predicted by VitD 
use for any of the 3 vaccine strains (A/H1N1, A/H3N2, and influenza B). 
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Table 1. Summary of clinical trials and observational studies evaluating the influence of VitD serum level and multiple VDR single nucleotide 
polymorphisms (SNP/haplotype) on the vaccine immunogenicity in humans. 
Vaccines Reference 
Study VitD Supplementation VitD Status  
(post-Replacement) 
Results 
Design Population Dosage (IU) Duration 
Influenza Kriesel et al. [64] RCT 175 adults (USA) 40 ** One dose NR A 
Hepatitis B Moe et al. [68] RCT 31 haemodialysis patients (USA) 144 μg * 12 weeks NR A 
Herpes Zoster Ginde et al. [69] SGA 
150 nursing home residents  
(60 years old or over—USA) 
High dose vs. normal dose 4 months ? ? 
    VDR SNPs/Haplotype   
Measles 
Ovsyannikova  
et al. [61] 
SGA 
745 healthy children genotyped for  
the 391 polymorphisms in their VDR  
(11–22 years old—USA) 
Association between multiple  
VDR SNPs/haplotype and  
vaccine adaptive immune response 
NR C 
Rubella 
Ovsyannikova  
et al. [62] 
SGA 
714 healthy children genotyped for the  
148 candidate SNPs (11–19 years old—
USA) 
Association between polymorphism in VDR 
and vaccine adaptive immune response 
NR C 
    Yearly Season of Inoculation   
Rubella Linder et al. [70] SGA 
Children aged 4–5 years (Israel) divided  
in 3 groups according to the season of the  
year in which vaccination was performed 
The association between vaccine 
immunogenicity and with sunlight  
variability-related to yearly season 
NR C 
S = serum 25(OH)D3 significantly increased and/or corrected deficiency. The exact % of the population who achieved desirable levels is mentioned between brackets when informed; NS = No 
significant difference between the two groups; NR = Not reported; RCT: Randomized controlled trial; SGA: single group assignment; VitD: vitamin D; VDR: VitD receptor; SNPs: single 
nucleotide polymorphisms; IU: international unit; * paricalcitol = 19-nor-1,25(OH)2D2, being an analog of 1,25-dihydroxyergocalciferol, the active form of VitD2; ** intramuscularly 
administered; A = No study end-points met, NEGATIVE study; B = All study end-points met, POSITIVE study; C = Some study end-points met, MIXED study. 
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Similarly, in a randomized controlled trial (RCT) conducted in thirty-one haemodialysis patients with 
standard hepatitis B booster vaccine, the intravenous administration of 4 μg of paricalcitol (i.e., an analog 
of the active form of VitD2) with the haemodialysis session three times weekly over 12 weeks were 
compared to placebo. The in vivo memory response and in vitro proliferation and release of IL-2, IL-6, 
TNF-α, and INF-γ were not different between the groups [68]. In contrast to clinical immune effects, 
paricalcitol increased serum calcium levels and decreased further PTH and bone alkaline phosphatase 
levels significantly. However, patients were not under VitD supplementation at baseline and both exact 
serum 25(OH)VitD at baseline and after complementation were not reported. Finally, one RCT is 
ongoing to determine the increase in the 3 weeks post-vaccination specific cell-mediated immune 
response from herpes zoster vaccination in 150 nursing home residents (60 years old or older) after  
4 months of high dose vs. standard dose VitD3 supplementation [69] (final data collection and primary 
outcome measure: December 2014). Interestingly, specific allelic variations and haplotypes of the VDR 
genes seem to also modulate the specific immune response to vaccine. Using a tag SNP (i.e., representative 
single nucleotide polymorphism) approach, 745 healthy children were genotyped for the 391 
polymorphisms in their VDR genes [61]. Significant associations between multiple VDR 
SNPs/haplotypes and measles-specific IL-2, IL-6, IL-10, IFN-α, IFN-γ, IFNλ-1, and TNF-α cytokine 
secretions were found. This suggests that allelic variations and haplotypes in the VDR genes influence 
adaptive immune responses to measles vaccine. Similarly, Ovsyannikova et al. [62] genotyped  
714 healthy children for 148 candidate SNP markers and presented evidence that, after two doses of 
rubella-vaccine, polymorphisms in VDR, but also in genes modulating innate immunity influence 
adaptive cytokine responses. 
Finally, it has been analyzed whether the season of inoculation may modulate the immune response 
to vaccination. Indeed, the yearly seasons are marked by changes in the amount of sunlight and  
UV-radiation is known to adversely affect the course of viral infections, immunologic memory and 
cellular and humoral immune responses [3,7]. Linder et al. have thus investigated potential differences 
in the immune response to the rubella vaccine after 3–4 years by season of inoculation in children aged 
4–5 years attending four kindergartens in villages in northern Israel [70]. All of them had been vaccinated 
at 1 year of age. Participants were divided into three groups according to the season of the year in which 
the vaccination was performed. Of the 203 children tested, 186 (91.6%) had adequate antibody levels,  
7 (3.4%) had equivocal levels and 10 (4.9%) had inadequate levels. Significantly higher mean 
geometrical titers were found in the winter-inoculated compared with the summer-inoculated group. The 
same tendency was noted in the percent of infants properly immunized. Thus, this preliminary study 
suggests that booster vaccine immunogenicity may be improved by inoculating children during seasons 
of less sunlight or by reducing the children’s exposure to sunlight following inoculation. However, 
further studies are needed to corroborate and expand these controversial findings. 
6. Conclusions 
Indubitably, the current idea that 25(OH)VitD and 1,25(OH)2VitD are more than just key players in 
bone formation is acceptable. This review has clearly shown that the cellular component of both arms 
of the immune system are not only targets for the active form of VitD but are also able to activate 
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circulating 25(OH)VitD arguing for intracrine and paracrine activities in addition to the classic  
endocrine pathway. 
While the current understanding supports the view that VitD insufficiency/deficiency increases 
susceptibility to various pathogens [7], its potential impact on vaccine immunogenicity is far from being 
demonstrated. Thus the concept that VitD is better than any vaccine or could be an immune or vaccine 
booster is not proved yet. Indeed, the underlying mechanisms that may lead to immunogenicity 
enhancement (or vaccine hyporesponsiveness according to VitD status) are yet to be clarified and further 
investigated. Although evidence about skeletal benefits supports the need of maintaining 25(OH)VitD 
at the desirable level, our understanding of non-classical immunological actions of VitD is far from 
complete. Moreover, the current target serum concentration of 75 nmol/L and dosage recommendations 
for VitD revolves around its application in bone health, while the effective dose eliciting an effect of the 
immune system in vivo remains to be determined. Thus, there is not yet sufficient information to clarify 
the true relationship between VitD status and vaccine immunogenicity. Therefore, it is still premature to 
recommend “booster” VitD supplementation at vaccination time to enhance vaccine response. 
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